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        Macrophages (M    s) are key participants in in-
nate immunity and contribute to the infl  am-
matory response in part through the secretion 
of chemokines and cytokines that recruit and 
activate other immune cells. Despite the bene-
fi  cial role of infl  ammatory mediators in host 
defense, their sustained production can lead to 
serious, chronic pathological conditions, such 
as atherosclerosis and rheumatoid arthritis. There-
fore, although necessary for the elimination of 
pathogens, excessive and prolonged M     acti-
vation leads to serious deleterious eff  ects in 
the host (  1, 2  ). 
  Chemerin is a chemoattractant protein pre-
sent in a range of human infl  ammatory exu-
dates, including ascitic and synovial fl  uid (  3, 4  ). 
Human prochemerin is secreted as a 142  –  amino 
acid (aa) precursor (145-aa  Mus musculus  ), which 
undergoes C-terminal truncation to generate a 
136-aa chemoattractant, chemerin (139-aa   Mus 
musculus  ) (  3, 5  –  7  ). Chemerin was identifi  ed as a 
natural ligand for the orphan heptahelical re-
ceptor ChemR23 through G protein  –  coupled 
receptor (GPCR) screening assays. 
  ChemR23 is a G      i  -linked receptor expressed 
primarily by monocytes, M    s, and plasmacy-
toid dendritic cells (  7, 8  ). ChemR23 shares 
phylogenetic homology with other chemoat-
tractant receptors, including those for the an-
tiinfl  ammatory mediator lipoxin A  4   and the 
neutrophil chemotaxins C5a and C3a (  3, 7, 9  ). 
Extracellular terminal proteolysis is characteris-
tic of ligands for some of these related receptors 
and appears to be used to modulate ligand bio-
activites (  3, 7, 9  ). At the time of writing, an-
other receptor for chemerin, the GPCR GPR1, 
has been identifi  ed (  10  ). 
  In addition to chemerin, ChemR23 binds 
an eicosapentenoic acid  –  derived lipid termed 
resolvin E1 (RvE1) (  11  ). RvE1 is thought to 
exert antiinfl  ammatory eff  ects through activa-
tion of ChemR23 and has recently been found 
to be a ligand for the related receptor BLT1 
(  12  ). RvE1 suppresses infl  ammation in animal 
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  Chemerin is a chemotactic protein that binds to the G protein  –  coupled receptor, ChemR23. 
We demonstrate that murine chemerin possesses potent antiinfl  ammatory properties that 
are absolutely dependent on proteolytic processing. A series of peptides was designed, and 
only those identical to specifi  c C-terminal chemerin sequences exerted antiinfl  ammatory 
effects at picomolar concentrations in vitro. One of these, chemerin15 (C15; A  140  -A  154  ), 
inhibited macrophage (M    ) activation to a similar extent as proteolyzed chemerin, but 
exhibited reduced activity as a M     chemoattractant. Intraperitoneal administration of C15 
(0.32 ng/kg) to mice before zymosan challenge conferred signifi  cant protection against 
zymosan-induced peritonitis, suppressing neutrophil (63%) and monocyte (62%) recruit-
ment with a concomitant reduction in proinfl  ammatory mediator expression. Importantly, 
C15 was unable to ameliorate zymosan-induced peritonitis in ChemR23      /      mice, demon-
strating that C15  ’  s antiinfl  ammatory effects are entirely ChemR23 dependent. In addition, 
administration of neutralizing anti-chemerin antibody before zymosan challenge resulted in 
a signifi  cant exacerbation of peritoneal infl  ammation (up to 170%), suggesting an impor-
tant endogenous antiinfl  ammatory role for chemerin-derived species. Collectively, these 
results show that chemerin-derived peptides may represent a novel therapeutic strategy for 
the treatment of infl  ammatory diseases through ChemR23. 768 CHEMERIN-DERIVED PEPTIDES ARE POTENT ANTIINFLAMMATORY MEDIATORS | Cash et al.
  Design of chemerin peptides and assays for their bioactivity 
  Previous studies have indicated that the biological activity of 
chemerin depends upon C-terminal processing (  6, 14  ). We 
therefore postulated that peptides formed upon C-terminal 
truncation could be responsible for the observed proteolysis-
dependent eff  ects of chemerin on M     activation. Conserved 
residues were identifi  ed by aligning the sequences of putative 
chemerin orthologs from several species using the ClustalW 
algorithm. A series of 11  –  20-aa peptides was designed and 
named C11 (P  144  -A  154  ; PHGYFLPGQFA), C13 (P  144  -S  156  ; 
PHGYFLPGQFAFS), C15 (A  140  -A  154  ; AGEDPHGYFLP-
GQFA), C19 (A  138  -S  156  ; AQAGEDPHGYFLPGQFAFS), 
N19 (E  23  -K  41  ; ELSETQRRSLQVALEEFHK), and M20 
(K  86  -K  105  ; KPECTIKPNGRRRKCLACIK). C-terminal pep-
tides C13 and C19 moderately suppressed LPS/IFN-      – 
induced RANTES and TNF-     expression with an optimal dose 
of 100 pM (  Table I  ).   Chemerin15 (C15), however, retained 
the antiinfl  ammatory activity shown by proteolyzed chemerin 
and inhibited cytokine expression with similar effi   cacy and po-
tency as chemerin (optimal dose, 1 pM). In addition, C11, the 
N-terminal peptide (N19), midstream peptide (M20), and the 
control peptides (scrambled C15 [C15-S], GLFHDQAGPPA-
GYEF, and mutant C15 [C15-M], AGEDPHGY A  LPGQ  A  A) 
were devoid of antiinfl  ammatory activity in the M     activation 
assay. The 6-aa (R  157  -K  162  ; RALRTK) and 8-aa (F  155  -K  162  ; 
FSRALRTK) peptides removed during prochemerin cleavage 
by proteases during coagulation, allergy, and tissue injury (  5  ), 
named C6 and C8, respectively, also possessed no detectable 
antiinfl  ammatory activity in the M     activation assay. 
  M     chemoattractant properties of chemerin 
and its C-terminal  –  derived peptides 
  We confi  rmed previous reports that murine chemerin is a M     
chemoattractant in modifi  ed Boyden chamber assays over a 
dose range of 10 pM to 50 nM (Fig. S1 A, available at http://
www.jem.org/cgi/content/full/jem.20071601/DC1). C11, 
C13, and C15 (1 pM  –  100 nM; Fig. S1, B  –  D) possessed little 
M     chemotactic activity compared with chemerin or a posi-
tive control, the CC chemokine RANTES (25 ng/ml; 3 nM). 
Maximal M     migration was observed with 100 pM C15, 
10 nM C13, and 10 nM C11 and was PTX sensitive. C19, 
however, displayed no chemotactic activity at all concentra-
tions tested (0.1 pM  –  500 nM; Fig. S1 E). Thus, we were able 
to identify a chemerin-derived peptide that retains antiinfl  am-
matory activity but exhibits no chemotactic activity for M    s, 
indicating the existence of distinct function-specifi  c compo-
nents of chemerin that could be exploited therapeutically. The 
prochemerin-derived peptides C6 and C8, which were found 
to be devoid of M     antiinfl  ammatory activity, were also inca-
pable of inducing M     migration at all concentrations tested 
(0.1 pM  –  500 nM; Fig. S1, F and G). 
  Ablation of the ChemR23 gene impairs antiinfl  ammatory 
and chemotactic effects of chemerin and C15 
  We next investigated whether the eff  ects of chemerin and 
C15 in our in vitro models of M     activation and chemotaxis 
models, including sulfonic acid  –  induced colitis and zymosan-
induced peritonitis (  11, 13  ). 
  We show for the fi  rst time that chemerin undergoes pro-
teolytic cleavage to generate potent antiinfl  ammatory pro-
ducts that can exert profound antiinfl  ammatory eff  ects in vitro 
at low picomolar concentrations. A single injection of a synthe-
tic chemerin-derived peptide signifi  cantly reduces zymosan-
induced peritonitis, and injection of an anti-chemerin antibody 
(ChAb) increases neutrophil and monocyte recruitment by 
up to 170%. 
    RESULTS AND DISCUSSION   
  Chemerin exerts antiinfl  ammatory effects on activated 
M    s in a proteolysis-dependent manner 
  To investigate the potential antiinfl   ammatory action of 
chemerin, we fi  rst evaluated the eff  ect of murine chemerin 
on the production of infl  ammatory mediators by peritoneal 
M    s (PM    s) elicited by Bio-Gel polyacrylamide beads and 
stimulated with LPS and IFN-    . PM    s were pretreated with 
chemerin for 1 h followed by a 15-h challenge with LPS/
IFN-     to induce classical M     activation. Chemerin inhib-
ited the production of the proinfl  ammatory mediators TNF-     
(70%), IL-1     (60%), IL-6 (42%), IL-12 p40 (54%), and 
RANTES (40%) by classically activated M    s (  Fig. 1 A  ).   In 
addition, chemerin induced the expression of mRNA for the 
antiinfl  ammatory cytokines TGF-     (twofold) and IL-10 (10-
fold). These eff  ects were dose dependent, with maximal re-
sponses observed at 1 pM (  Fig. 1 A  ), and pertussis toxin (PTX) 
sensitive, indicating the involvement of a G      i  -linked GPCR 
(  Fig. 1 B  ). In addition, antiinfl  ammatory eff  ects were observed 
at 4, 8, and 15 h after LPS/IFN-     administration and were 
abrogated by PTX at all time points (  Fig. 1 C  ). 
  Previous studies have demonstrated that serine proteases 
released by granulocytes upon degranulation cleave the C-
terminal extremity of prochemerin and release its chemotactic 
potential (  6  ). We therefore investigated the possibility that 
murine chemerin could undergo proteolytic processing by 
enzymes released upon murine M     activation. Coadminis-
tration of chemerin with leupeptin (a serine and cysteine 
protease inhibitor) or E-64 (a cysteine protease inhibitor) 
abolished its antiinfl  ammatory eff  ects (  Fig. 1 D  ), whereas the 
acidic protease inhibitor pepstatin A and the serine protease 
inhibitor pefabloc exerted no eff  ect on chemerin-mediated 
suppression of M     activation. These data demonstrate that 
chemerin exerts inhibitory eff  ects on M     activation in a cys-
teine protease  –  dependent manner. A cathepsin L inhibitor 
(Z-FF-FMK), cathepsin S inhibitor (Z-FL-COCHO), and a 
calpain I and II inhibitor (calpeptin) were used to further 
probe the specifi  c cysteine proteases involved in chemerin 
cleavage. It was found that chemerin  ’  s antiinfl  ammatory ef-
fects were dependent on calpains and cathepsin S but were 
independent of cathepsin L. Collectively, our results demon-
strate for the fi  rst time that classically activated M    s are capable 
of converting chemerin into potent antiinfl  ammatory pep-
tides by cysteine protease  –  mediated cleavage of the parent 
molecule, most likely involving calpains and cathepsin S. JEM VOL. 205, April 14, 2008  769
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    Figure 1.         Antiinfl  ammatory activity of chemerin on activated M    s is proteolysis dependent.   (A – D)  PM   s were pretreated with 1 pM chemerin 
(Chem), 1 pM chemerin plus protease inhibitor (leupeptin [Leu], E-64, pefabloc [Pef], pepstatin A [Pep A], calpeptin [Cal], cathepsin S inhibitor [Cath S], 
cathepsin L inhibitor [Cath L]), or 1   μ  M dexamethasone (Dexa) for 1 h and then stimulated with 100 ng/ml LPS and 20 ng/ml IFN-     for 15 h. Cytokine 
expression in M     supernatants after 16 h was determined by Luminex assays. mRNA levels were quantifi  ed by quantitative RT-PCR (IL-10, TGF-   )  and 
normalized to HPRT. (B) PM    s were pretreated with 0.1  –  1 pM chemerin   ±   200 ng/ml PTX before LPS/IFN-     challenge. (C) PM    s were pretreated with 1 pM 
chemerin for 1 h   ±   PTX and then stimulated with LPS/IFN-     for 4, 8, or 15 h. ***, P   <   0.001; **, P   <   0.01; *, P   <   0.05 relative to LPS/IFN-    – treated  samples; 
###, P   <   0.001; ##, P   <   0.01; #, P   <   0.05 relative to chemerin-treated samples. Graphs show mean values   ±   SEM from three to eight independent experi-
ments. nd, below limit of detection for this assay. ns, not signifi   cant.   770 CHEMERIN-DERIVED PEPTIDES ARE POTENT ANTIINFLAMMATORY MEDIATORS | Cash et al.
  The chemotactic eff  ects of chemerin and C15 were com-
pletely ablated in ChemR23 KO M    s, indicating that induc-
tion of M     chemotaxis by chemerin and C15 is entirely 
ChemR23 dependent (  Fig. 2, A and B  ).   M     migration to-
ward prototypical chemoattractants RANTES and fMLP was 
unaff  ected in M    s from ChemR23      /      mice (Fig. S2, F and 
G), demonstrating that ChemR23      /      M    s exhibited selec-
tive impairment of chemerin and C15-mediated chemotaxis. 
  C15 was unable to suppress proinfl  ammatory mediator 
production by ChemR23 KO M    s, indicating that its 
were mediated via the chemerin receptor ChemR23 through 
the use of KO mice. PCR and Southern blot analysis con-
fi  rmed the presence of a disrupted ChemR23 allele in het-
erozygote and homozygote KO mice and the presence of a 
wild-type ChemR23 allele in heterozygote and wild-type 
animals (Fig. S2, A  –  C, available at http://www.jem.org/cgi/
content/full/jem.20071601/DC1). Furthermore, chemerin was 
found to induce calcium fl  ux in wild-type Bio-Gel  –  elicited 
peritoneal cells, but failed to do so in cells from ChemR23 
KO mice (Fig. S2, D and E). 
  Table I.  Antiinfl  ammatory activity of chemerin-derived peptides 
Percentage inhibition of LPS/IFN-      –  induced infl  ammatory cytokine expression
Cytokine Chemerin C6 C8 C11 C13 C15 C15-S C15-M C19 N19 M20
TNF-    70 0 0 0 10 61 0 0 21 0 0
RANTES 40 0 0 0 32 47 0 0 41 0 0
IL-1    60   —   —   —   — 54   —   —   —   —   — 
IL-12p40 54   —   —   —   — 47   —   —   —   —   — 
IL-6 42   —   —   —   — 43   —   —   —   —   — 
PM    s were challenged with 100 ng/ml LPS and 20 ng/ml IFN-     for 15 h with or without pretreatment with peptides (0.1 pM  –  100 nM) for 1 h. Where peptides exhibited 
antiinfl  ammatory properties, percentage inhibition of LPS/IFN-    – induced  M    activation represents effect with optimal dose (1 pM chemerin and C15 or 100 pM C13 and 
C19). Peptide sequences are as follows: C6 (R  157 -K 162  ; RALRTK), C8 (F  155 -K 162  ; FSRALRTK), C11 (P  144 -A 154  ; PHGYFLPGQFA), C13 (P  144 -S 156  ; PHGYFLPGQFAFS), C15 (A  140 -A 154 ; 
AGEDPHGYFLPGQFA), C19 (A  138 -S 156  ; AQAGEDPHGYFLPGQFAFS), N19 (E  23 -K 41  ; ELSETQRRSLQVALEEFHK), and M20 (K  86 -K 105  ; KPECTIKPNGRRRKCLACIK). Control peptides: C15-S 
(GLFHDQAGPPAGYEF) and C15-M (AGEDPHGY  A LPGQ A  A; F148A and F153A). Data represent mean percentage inhibition of cytokine production by classically activated M   s 
from four to eight independent experiments as determined by ELISAs and Luminex assays.
    Figure 2.         Effects of chemerin and C15 peptide are impaired in M    s from ChemR23      /      mice.   (A and B) PM   s  (0.4   ×   10 6   cells) from wild-type 
and ChemR23     /     mice were allowed to migrate toward chemoattractant (chemerin or C15) in the bottom well of a modifi  ed Boyden chamber over 4 h. 
Filters were fi  xed in 4% formalin, and migrated cell nuclei were stained with DAPI, visualized, and quantifi  ed. Serum-free medium was used as a negative 
control and 25 ng/ml RANTES (migration index, 6   ±   0.59) as a positive control. Graphs indicate mean migration index   ±   SEM for each treatment group 
(  n   = 4 independent experiments). ***, P   <   0.001; **, P   <   0.01; *, P   <   0.05 relative to migration induced by the same concentration of chemoattractant in 
ChemR23     /     PM   s. (C and D) PM    s from wild-type and ChemR23     /     mice were pretreated with 0.1  –  1 pM C15 (C) or 0.1  –  1 pM chemerin (D) for 1 h and 
then stimulated with 100 ng/ml LPS and 20 ng/ml IFN-     for 15 h. Mean expression of cytokines   ±   SEM in M     supernatants after 16 h was determined by 
ELISA (  n   = 4 independent experiments). **, P   <   0.01; *, P   <   0.05 relative to LPS/IFN-      –  treated samples. ns, not signifi   cant.   JEM VOL. 205, April 14, 2008  771
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jem.20071601/DC1), although signifi  cant antiinfl  ammatory 
eff  ects were seen with a dose of 4 pg/mouse (    0.16 ng/kg; 
Fig. S3). When C15 was administered 1 h before zymosan 
challenge, neutrophil numbers were reduced from 1.9   ×   10  6   
to 0.78   ×   10  6   cells (63% decrease;   Fig. 3 C  ) and monocyte 
levels from 0.69   ×   10  6   to 0.30   ×   10  6   cells (62% decrease; 
  Fig. 3 D  ; representative FACS plots at the 4-h time point are 
shown in   Fig. 3 E  ). C15 administration also diminished peri-
toneal expression of proinfl  ammatory cytokines at 4 h, in-
cluding TNF-     (51%), IL-1     (67%), IL-6 (67%), JE (59%), 
and KC (38%;   Fig. 3 F  ). Control peptides C15-S and C15-
M, which were devoid of in vitro antiinfl  ammatory activity 
(  Table I  ), were not protective in vivo when given at the same 
dose and time as C15, as judged by neutrophil and monocyte 
levels (  Fig. 3, C and D  ). Suppression of neutrophil (1.9   ×   10  6   
to 0.83   ×   10  6   cells; 60% decrease) and monocyte recruitment 
(0.69   ×   10  6   to 0.42   ×   10  6   cells; 42% decrease) was still seen 
4 h after zymosan, when the same dose of C15 was given 2 h 
after zymosan injection (  Fig. 3 G  ). This demonstrates that 
C15 can reduce neutrophil and monocyte recruitment in an 
established infl  ammatory setting, providing another indica-
tion that C15/C15 derivatives may represent attractive phar-
macophores targeting infl  ammatory pathologies. 
  When the same experiments were performed in ChemR23     /      
mice, C15 administration was not able to suppress zymo-
san-induced monocyte and neutrophil recruitment, indicat-
ing complete dependence of C15  ’  s antiinfl  ammatory eff  ects 
upon ChemR23 (  Fig. 3 H  ). Furthermore, the infl  ammatory 
response of ChemR23      /      mice to zymosan was equivalent 
in magnitude to that of the wild-type controls in terms of 
neutrophil (  +/+  , 5.7   ±   0.37 vs.       /     , 5.5   ±   0.63 cells) and 
monocyte recruitment (  +/+  , 1.05   ±   0.09 vs.       /     , 0.96   ±   0.11 
cells;   Fig. 3 H  ). 
  Blockade of endogenous chemerin species exacerbates 
peritoneal infl  ammation 
  Given the apparent lack of ChemR23      /      phenotype in the 
zymosan-induced peritonitis model, we investigated a poten-
tial endogenous role for chemerin/chemerin-derived peptides 
by injecting mice i.p. with a neutralizing polyclonal ChAb or 
a control IgG 1 h before a 4- or 24-h zymosan challenge. We 
had previously shown that ChAb but not control IgG was ca-
pable of inhibiting C15 and chemerin-induced M     chemo-
taxis and antiinfl  ammatory eff  ects in vitro (  Fig. 4, A and B  ).   In 
vivo it was found that neutralization of endogenous chemerin 
species resulted in a rise in peritoneal neutrophil (63%) and 
monocyte (45%) levels at the 4-h time point relative to control 
IgG  –  treated mice and a 170 and 86% increase in peritoneal 
neutrophil and monocyte levels 24 h after zymosan injection 
(  Fig. 4, C and D  ). This exacerbation of peritoneal infl  amma-
tion over a 24-h period suggests an important antiinfl  amma-
tory role for endogenous chemerin species in vivo in controlling 
the magnitude of the innate immune response. The absence of 
an exaggerated infl  ammatory phenotype in ChemR23      /      
mice may be due to redundancy in the chemerin antiinfl  am-
matory system. In fact, an additional receptor for chemerin, 
  antiinfl  ammatory eff  ects in this model are completely mediated 
through ChemR23 (  Fig. 2 C  ). Interestingly, chemerin dis-
played a reduced but not completely abrogated antiinfl  am-
matory activity on ChemR23      /      M    s (  Fig. 2 D  ). These data 
are consistent with a model in which chemerin is cleaved by 
M    -derived proteases to generate antiinfl  ammatory peptides 
that act through multiple GPCRs, including but not exclu-
sively ChemR23. At the time of writing, a second receptor 
for chemerin, the GPCR GPR1, has been identifi  ed (  10  ). 
  C15 ameliorates zymosan-induced peritonitis 
in a ChemR23-dependent manner 
  The zymosan  –  peritonitis model (for review see reference   15  ) 
has been used to demonstrate the antiinfl  ammatory properties 
of dexamethasone (  16  ), annexin peptide (  17  ), and the lipid 
ChemR23 agonist RvE1 (  13  ), which typically suppress both 
infl  ammatory cell recruitment into the peritoneal cavity and 
proinfl  ammatory cytokine production. 
  Given the high chemotactic potential of chemerin and 
inherent requirement for proteolysis, we turned to the C-
terminal synthetic peptide C15 for in vivo characterization of 
antiinfl  ammatory eff  ects in the sterile peritonitis model be-
cause C15 is largely devoid of chemotactic activity (Fig. S1 B) 
yet exerts comparable antiinfl  ammatory eff  ects to those of 
proteolyzed chemerin (  Table I  ). To determine the antiin-
fl  ammatory properties of C15 in vivo, a time-course experi-
ment was performed extending over 48 h. Neutrophil 
(7/4  high  , Ly-6G  high  ) and monocyte (7/4  high  , Ly-6G  low  ) popu-
lations in peritoneal lavage fl  uid were determined by FACS 
analysis according to established protocols (  18, 19  ). Adminis-
tration of zymosan i.p. produced a time-dependent extrava-
sation of infl  ammatory cells into the peritoneal cavity, which 
followed the typical profi  le of an acute infl  ammatory response 
(  Fig. 3, A and B  , solid line).   Pretreatment with C15 (8 pg/
mouse;     0.32 ng/kg) 1 h before zymosan challenge brought 
the peak neutrophilia forward from 4 h post-zymosan admin-
istration to 2 h with     50% the magnitude of that of zymo-
san-challenged mice (reduced from 1.25   ×   10  6   to 0.62   ×   10  6   
cells;   Fig. 3 A  , dotted line). Suppression of neutrophil infi  l-
tration by C15 was seen at 2, (50%), 4 (66%), and 24 h (50%). 
A single dose of C15 peptide was also eff  ective in reducing 
monocyte levels in infl  amed cavities at all time points, with 
  >  60% suppression seen at 4 (63%), 8 (61%), and 48 h (64%; 
  Fig. 3 B  , dotted line). The rate of monocyte infi  ltration was 
highest 2  –  4 h after zymosan injection (0.51   ×   10  6   cells/h), 
and C15 administration reduced the rate of infl  ux (0.18   ×   10  6   
cells/h). A single dose of C15 peptide before zymosan chal-
lenge therefore provided signifi  cant protection against zymo-
san-induced peritoneal infl  ammation over 48 h. 
  The time-course experiment identifi  ed the 4-h post-
zymosan time point as an appropriate point for validation of 
C15  ’  s antiinfl  ammatory activity. In this study, a single dose of 
C15 produced a dose-dependent reduction in zymosan-elic-
ited neutrophil and monocyte recruitment, which was maxi-
mal at 8 pg/mouse C15 (    0.32 ng/kg;   Fig. 3, C  –  E  , and Fig. S3, 
which is available at http://www.jem.org/cgi/content/full/772 CHEMERIN-DERIVED PEPTIDES ARE POTENT ANTIINFLAMMATORY MEDIATORS | Cash et al.
native hypothesis is that the ChemR23 infl  ammatory axis may 
be of particular importance only in certain infl  ammatory pa-
thologies or that a ChemR23 KO phenotype may not mani-
fest except in the context of chronic infl  ammation. 
the GPCR GPR1, has now been reported, which may repre-
sent a second target for chemerin-derived peptides (  10  ). We 
therefore predict that ablation of the chemerin gene may result 
in mice with exaggerated infl  ammatory pathologies. An alter-
    Figure 3.         C15 ameliorates zymosan-induced peritonitis in a ChemR23-dependent manner.   C57Bl6/J mice were dosed i.p. with PBS or 0.32 ng/kg 
C15 followed by injection with PBS or 10   μ  g zymosan (   2   ×   10 6   particles per cavity) 1 h later. Peritoneal exudate cells (PECs) were harvested by perito-
neal lavage at multiple time points (A and B; fi  ve to six mice/group) or after 4 h (C  –  E; 6  –  15 mice/group). Total PECs were quantifi  ed, and cellular composi-
tion (neutrophils vs. monocytes) was determined by FACS analysis. Cells were stained with Ly-6G-PE and 7/4-FITC. Gates were constructed around two 
populations, the neutrophils (7/4  high ,  Ly-6G high  ) and monocytes (7/4  high ,  Ly-6G low  ). (E) Representative FACS plots are shown for each treatment group at 4 h 
after zymosan injection. (F) Peritoneal lavage fl  uid was assayed for TNF-    , KC, IL-6, IL-1    , and JE by Luminex assay. (G) Mice (six to eight/treatment) were 
dosed i.p. with 10   μ  g zymosan and with 8 pg C15 or PBS either 1 h beforehand (C15 pretreatment) or 2 h later (C15 post-zymosan). Peritoneal lavage was 
performed 4 h after zymosan challenge. (H) Wild-type and ChemR23     /     mice on a 129SvEv background were dosed i.p. with PBS or 0.32 ng/kg C15 fol-
lowed by injection with PBS or 10   μ  g zymosan 1 h later. PECs cells were harvested by peritoneal lavage 4 h after zymosan injection and characterized by 
FACS (six to eight mice/treatment). C15, chemerin15; Z, zymosan; ***, P   <   0.001; **, P   <   0.01 relative to zymosan-treated animals; nd, not detectable; ns, 
not signifi   cant.   JEM VOL. 205, April 14, 2008  773
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peritoneal exudates by up to 25% when administered at 300 ng/
mouse i.p. (12   μ  g/kg) (  23  ). The in vitro and in vivo con-
centrations of chemerin used in our experiments are     500-
fold lower than concentrations of chemerin found in murine 
plasma and serum (  8  ). This could mean that little endogenous 
chemerin may need to be present at sites of infl  ammation for 
antiinfl  ammatory eff  ects to become evident in vivo. 
  Here, we have demonstrated that chemerin exhibits anti-
infl  ammatory eff  ects on M    s in vitro in a proteolysis-depen-
dent fashion. We found that C-terminal chemerin peptides, 
in particular C15, exhibit potent antiinfl  ammatory properties in 
in vitro and in vivo models of infl  ammation when administered 
in the picogram range that are mediated through ChemR23. 
These fi  ndings suggest that C15/C15 derivatives may represent 
a novel therapeutic strategy for the treatment of infl  ammatory 
pathologies via ChemR23. 
  C-terminal chemerin peptides: novel 
antiinfl  ammatory mediators 
  Many endogenous proinfl  ammatory mediators have been de-
scribed, several of which are active in the picomolar range, in-
cluding TNF-     (10      11   M), fMLP (10      11   M), and IL-1 (10      14   M) 
(  20, 21  ). To our knowledge, our synthetic chemerin pep-
tides are the fi  rst antiinfl  ammatory mediators shown to be ac-
tive in vitro and in vivo in the picomolar range. Pharmaceutical 
preparations such as dexamethasone are commonly adminis-
tered at concentrations in the micromolar range in vitro (  22  ). 
Indeed, dexamethasone achieves a 50% suppression of mono-
cyte and neutrophil infl  ux in the zymosan-induced peritonitis 
model at 30   μ  g/mouse (1.2 mg/kg) (  16  ), whereas C15 pro-
duces equivalent antiinfl  ammatory eff  ects at a dose of 8 pg/
mouse (0.32 ng/kg). C15 is also more potent than the lipid li-
gand for ChemR23, RvE1, which reduces PMN numbers in 
    Figure 4.         ChAb neutralizes chemerin species and exacerbates peritoneal infl  ammation.   (A)  PM   s were used in M     chemotaxis assays (as de-
tailed in   Fig. 2  ) and allowed to migrate toward RANTES, chemerin, or C15   ±   ChAb or control IgG. Graphs indicate mean migration index   ±   SEM (  n   =  4 
independent experiments). ***, P   <   0.001; **, P   <   0.01 relative to chemoattractant. (B) PM    s were pretreated with 1 pM C15 or 1 pM chemerin   ±   ChAb or 
control IgG for 1 h and then stimulated with 100 ng/ml LPS and 20 ng/ml IFN-     for 15 h. Mean expression of RANTES   ±   SEM in M     supernatants  after 
16 h was determined by ELISA (  n   = 4 independent experiments). ***, P   <   0.001 relative to LPS/IFN-      –  treated samples. (C and D) C57Bl6/J mice were dosed 
i.p. with PBS, 100 ng/mouse ChAb, or 100 ng/mouse control IgG followed by injection with PBS or 10   μ  g/cavity zymosan 1 h later. PECs were harvested 4 
and 24 h after zymosan injection and processed as outlined in   Fig. 3  . Z, zymosan; ChAb, anti-chemerin antibody; **, P   <   0.01 relative to zymosan-chal-
lenged mice; ns, not signifi   cant.   774 CHEMERIN-DERIVED PEPTIDES ARE POTENT ANTIINFLAMMATORY MEDIATORS | Cash et al.
composition (neutrophils vs. monocytes) of peritoneal lavage fl  uid were ob-
tained by FACS analysis. In brief, 10  5   cells were blocked with anti  –  mouse 
2.4G2 Fc    II/III (0.5   μ  g/0.10  5   cells; Serotech) for 10 min and stained for 
10 min with FITC-conjugated anti  –  mouse 7/4 and PE-conjugated anti  –  mouse 
Ly-6G (0.5   μ  g/0.5   ×   10  6   cells; clones rmC5-3 and RB6-8C5, respectively; 
BD Biosciences). Gates were constructed around two populations, the neu-
trophils (7/4  high  , Ly-6G  high  ) and infl  ammatory monocytes (7/4  high  , Ly-6G  low  ). 
The percentage of total events in each population was obtained. In addition, 
cell-free lavage fl  uid was collected for use in ELISAs and Luminex assays. 
  Generation and characterization of ChemR23      /       mice.     ChemR23 is 
encoded by the Cmklr1 gene (Ensembl Gene ID, ENSMUSG00000042190). 
The gene-targeting vector was designed to delete the majority of the cod-
ing sequence from 33 bp after the initiating methionine to beyond the 
translational stop codon, thereby removing all but the fi  rst 12 of the 371 
protein residues and replacing them with an internal ribosome entry site 
LacZ reporter gene. Targeted embryonic stem cell clones were identifi  ed 
by PCR and confi  rmed by Southern blot analysis. Correctly targeted clones 
were used to generate chimeras that transmitted the ChemR23 KO allele 
at the expected Mendelian frequency. Heterozygous mice were viable and 
fertile as were the homozygous KO mice. PCR was performed with the 
following primers: P1, 5    -CCCAGTCACAGGAGCTTCACCAAGATG-3    ; 
p2, 5   -AATGGCCGCTTTTCTGGATTCATCGAC-3    ; and p3, 5   -ATG-
AGCCGCCTTGTGCAAAATTCAGTG-3    . DNA fragments were ana-
lyzed by agarose gel electrophoresis. A product of 378 bp (neomycin insert) 
corresponded to the       /      genotype, a 215 bp product (ChemR23) corre-
sponded to the   +  /  +   genotype, and the presence of both the 215- and 378-bp 
products indicated the       /+   genotype. 
  Calcium fl  ux.     4-d Bio-Gel  –  elicited cells were harvested and resuspended 
in HBSS with CaCl  2   and MgCl supplemented with 0.5% BSA and 10 mM 
Hepes (HBSS/BSA) at room temperature to a cell density of 10  7   cells/ml. 
The cell suspension was incubated with 2   μ  M Fura-PE3/AM (EMD) for 
45 min at room temperature. The cells were then washed twice and resus-
pended in HBSS/BSA (3   ×   10  7   cells/ml). 100   μ  l of cell suspension (3   ×   10  6   
cells) was added to a cuvette containing 400   μ  l of prewarmed (37  °  C) HBSS/
BSA and placed in a luminescence spectrometer (LS55; PerkinElmer). After 
a period of at least 60 s, fl  uorescence measurements were recorded at excita-
tion wavelengths of 340 and 380 nm and an emission wavelength of 510 nm. 
10   μ  l of agonist was added under constant stirring at appropriate intervals. 
At the end of each experiment, 10   μ  l 10% Triton X-100 was added to deter-
mine maximum calcium fl  ux. 
  Statistics.     Student  ’  s   t   test and one-way ANOVA (with Tukeys post-hoc 
test) were performed using GraphPad Prism software. 
  Online supplemental material.     Fig. S1 shows M     chemotaxis induced 
by chemerin and chemerin-derived peptides. Fig. S2 provides detailed 
methods for the generation and characterization of ChemR23      /      mice, in-
cluding Southern blots and targeting constructs, Ca  2+   fl  ux, and chemotaxis 
data. Fig. S3 shows the dose-dependent antiinfl  ammatory eff  ects of C15 in 
zymosan-induced peritonitis. 
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  MATERIALS AND METHODS 
  Animals.     All animal studies were conducted with ethical approval from the 
Dunn School of Pathology Local Ethical Review Committee and in accor-
dance with the UK Home Offi   ce regulations (Guidance on the Operation of 
Animals, Scientifi  c Procedures Act, 1986). 
  M     activation assays.     Bio-Gel P100 polyacrylamide beads (1 ml of 2% wt/
vol in PBS; Bio-Rad Laboratories) were injected into the peritoneal cavity 
of 8  –  12-wk-old C57BL/6 mice. 4 d later, mice were killed and perito-
neal exudates collected in PBS plus 2 mM EDTA. Harvested cells were 
centrifuged and resuspended in OptiMEM medium (Invitrogen) supple-
mented with 2 mM glutamine (Invitrogen), 50 U/ml penicillin, and 50   μ  g/
ml streptomycin (Invitrogen). Cells (1.5   ×   10  6  /well) were plated in six-well 
tissue culture plates (35-mm diameter; Costar) and allowed to adhere for 2 h 
at 37  °  C in a humidifi  ed atmosphere containing 5% CO  2   to isolate M     pop-
ulations by adherence. Nonadherent cells were removed by washing with 
PBS after 2 h. Adherent cells were judged to be   >  95% M    s by morphologi-
cal criteria. M    s were preincubated with 10      12    –  10      8   M rmChemerin (R  &  D 
Systems), 10      12    –  10      8   M chemerin peptides (Bio-Synthesis Inc.), or 1   μ  M 
dexamethasone (Sigma-Aldrich) for 1 h and then challenged with 100 ng/ml 
LPS (Sigma-Aldrich) and 20 ng/ml IFN-     (PeproTech) for 15 h. Protease 
inhibitors (Sigma-Aldrich and EMD) were administered with chemerin to 
determine dependency upon proteolysis. M     media were harvested and 
stored at     80  °  C until use in ELISAs (R  &  D Systems) and Luminex assays 
(Bio-Rad Laboratories). Protease inhibitors were used at the following con-
centrations: leupeptin, 15   μ  g/ml; E-64, 5   μ  M; pefabloc, 10   μ  M; pepstatin A, 
1   μ  M; calpeptin, 5   μ  M; cathepsin S inhibitor, 250 nM; cathepsin L inhibitor, 
1   μ  M. Chemerin peptides were prepared by Bio-Synthesis Inc., and purity 
was assessed to be   >  95% as assessed by HPLC and mass spectrometry (data 
provided by the manufacturer). Chemerin and chemerin-derived peptides 
were not found to aff  ect cell viability adversely as determined using the MTS 
assay (Promega) and had no detectable endotoxin as judged by Limulus ame-
bocyte lysate assay (Cambrex). 
  Detection of secreted protein by ELISAs and Luminex.     RANTES, 
TNF-    , and KC concentrations in cell supernatants and peritoneal fl  uid 
were assessed by ELISA (R  &  D Systems). IL-12 p40, IL-1    , TNF-    , JE, and 
IL-6 levels were determined by Luminex multiplex bead assay (Bio-Rad 6 
plex assay). Detection limits were 100 pg/ml for ELISAs and 10  –  50 pg/ml 
for Luminex assays depending on cytokine. 
  RNA preparation and RT-PCR.     Total RNA was extracted using QIAGEN 
RNeasy kits, reverse transcribed, and subjected to quantitative RT-PCR using 
the Sybr-Green method. Data were analyzed using the 2              CT   method (  24  ). 
  Chemotaxis assay.     4   ×   10  5   Bio-Gel-elicited M    s were harvested and 
placed on 96-well Neuroprobe membranes (6-mm diameter, 8-  μ  m pore size; 
ChemoTX) in RPMI supplemented with 25 mM Hepes (Invitrogen) and 
0.1% BSA (Sigma-Aldrich). Cells were allowed to migrate toward 1 pM  –  100 nM 
chemerin peptides, 1 pM  –  50 nM chemerin, 25 ng/ml RANTES (Pepro-
Tech), or serum-free media for 4 h. Signal transduction via G      i   was blocked 
by preincubating cells with 200 ng/ml PTX (Sigma-Aldrich) for 30 min be-
fore chemotaxis assays. Migrated cells on the underside of membranes were 
fi  xed (3% formalin) and stained with DAPI. Migration was quantifi  ed as total 
pixel count of DAPI (Sigma-Aldrich) -stained nuclei under the fl  uorescence 
microscope (two photos/membrane and a minimum of three replicate wells 
per treatment). Images were analyzed using Metamorph software to deter-
mine percentage threshold areas (TA) occupied by migrated cells. Migration 
indices were obtained by dividing treatment TA by serum-free media TA. 
  Murine peritonitis.     C57BL6/J mice were administered 500   μ  l C15 (0.32 ng/
kg) or vehicle (PBS) i.p. 1 h before administration of 500   μ  l of 10   μ  g zymosan 
A (Sigma-Aldrich) i.p. After 2, 4, 8, 16, 24, and 48 h and after mice were 
killed, peritoneal exudates were collected by peritoneal lavage with 5 ml of 
sterile PBS-3 mM EDTA. Total cell counts were determined, and the cellular JEM VOL. 205, April 14, 2008  775
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